The role of the bone microenvironment in regulating myeloma residual disease and treatment.

Front Oncol · 2022 · PMC9441696 · PMID 36072809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Results from a phase Ib trial on BHQ-880 showed a trend to increased bone mineral density, and whilst the phase II trial is complete no detailed results have been published.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.